Summary of Study ST002064
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001307. The data can be accessed directly via it's Project DOI: 10.21228/M8S124 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST002064 |
| Study Title | Metabolic impact of anticancer drugs Pd2Spermine and Cisplatin on the polar extracts of brain from healthy mice (part 1) |
| Study Type | NMR-based metabolomics |
| Study Summary | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on polar metabolism of brain from healthy mice at 1, 12 and 48 h post-injection times. |
| Institute | University of Aveiro |
| Department | Department of Chemistry and CICECO-Aveiro Institute of Materials |
| Laboratory | Metabolomics from Ana M. Gil |
| Last Name | Carneiro |
| First Name | Tatiana João |
| Address | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
| tatiana.joao@ua.pt | |
| Phone | +351926369478 |
| Submit Date | 2022-01-10 |
| Num Groups | 9 |
| Total Subjects | 45 |
| Num Females | 45 |
| Raw Data Available | Yes |
| Analysis Type Detail | NMR |
| Release Date | 2022-02-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001307 |
| Project DOI: | doi: 10.21228/M8S124 |
| Project Title: | Biochemical Impact of Platinum and Palladium-based Anticancer Agents – BioIMPACT |
| Project Type: | NMR-based metabolomics |
| Project Summary: | Platinum (Pt(II)) drugs, e.g. cisplatin (cDDP), are some of the most used chemotherapeutic agents, yet tumor acquired resistance and high toxicity are still current drawbacks. Palladium (Pd(II))-complexes are alternatives due to similar metal coordination and promising cytotoxic properties. Metabolomics can measure the metabolic response of drug-exposed tissues, unveiling insight into drug mechanisms and new markers of drug efficacy/toxicity. The present 1H NMR metabolomics study aims to characterize the in vivo response of the impact of a Pd(II)-complex with polyamine spermine (Pd2Spm), compared to cDDP, on the metabolism of several organs from healthy mice. |
| Institute: | University of Aveiro |
| Department: | Department of Chemistry and CICECO-Aveiro Institute of Materials |
| Laboratory: | Metabolomics from Ana M. Gil |
| Last Name: | Carneiro |
| First Name: | Tatiana J. |
| Address: | Campus Universitário de Santiago, Aveiro, Aveiro, 3810-193, Portugal |
| Email: | tatiana.joao@ua.pt |
| Phone: | +351926369478 |
| Funding Source: | This research was developed within the scope of the CICECO—Aveiro Institute of Materials, with references UIDB/50011/2020 and UIDP/50011/2020, financed by national funds through the Por-tuguese Foundation for Science and Technology (FCT/MEC) and when appropriate co-financed by European Regional Development Fund (FEDER) under the PT2020 Partnership Agreement. This work was also funded by the FCT through LAQV/REQUIMTE FCT UIDB/50006/2020 (C.D.), UIDB/00070/2020 (A.L.M.B.d.C and M.P.M.M.), POCI-01-0145-FEDER-0016786, and Cen-tro-01-0145-FEDER-029956 (co-financed by COMPETE 2020, Portugal 2020 and European Com-munity through FEDER). We also acknowledge the Portuguese National NMR Network (PTNMR), supported by FCT funds as the NMR spectrometer used is part of PTNMR and partially supported by Infrastructure Project Nº 022161 (co-financed by FEDER through COMPETE 2020, POCI and PORL, and the FCT through PIDDAC). M.V. thanks the FCT and the PhD Program in Medicines and Pharmaceutical Innovation (i3DU) for his PhD grant PD/BD/135460/2017 and T.J.C. thanks FCT for her PhD grant SFRH/BD/145920/2019; both grants were funded by the European Social Fund of the European Union and national funds FCT/MCTES. |
Subject:
| Subject ID: | SU002146 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Genotype Strain: | BALB/cByJ |
| Age Or Age Range: | 6-weeks |
| Weight Or Weight Range: | 20.1 g |
| Gender: | Female |
| Animal Animal Supplier: | Charles River Laboratories (France) |
| Animal Housing: | ICBAS-UP Rodent Animal House Facility (Porto, Portugal) |
| Animal Light Cycle: | 12h light/dark cycles (7.00 AM lights on) |
| Animal Feed: | ad libitum |
| Animal Water: | ad libitum |
| Animal Inclusion Criteria: | Healthy animails |
| Species Group: | BALB/cByJ |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Treatment_group |
|---|---|---|
| SA194181 | healthy_B_EA_B4_2_1_2 | Cisplatin_12h |
| SA194182 | healthy_B_EA_B4_3_1_2 | Cisplatin_12h |
| SA194183 | healthy_B_EA_B4_5_1_2 | Cisplatin_12h |
| SA194184 | healthy_B_EA_B4_1_1_2 | Cisplatin_12h |
| SA194185 | healthy_B_EA_B4_4_1_2 | Cisplatin_12h |
| SA194186 | healthy_B_EA_B2_2b_1_2 | Cisplatin_1h |
| SA194187 | healthy_B_EA_B2_4_1_2 | Cisplatin_1h |
| SA194188 | healthy_B_EA_B2_3_1_2 | Cisplatin_1h |
| SA194189 | healthy_B_EA_B2_1_1_2 | Cisplatin_1h |
| SA194190 | healthy_B_EA_B2_5_1_2 | Cisplatin_1h |
| SA194191 | healthy_B_EA_B6_1_1_2 | Cisplatin_48h |
| SA194192 | healthy_B_EA_B6_5_1_2 | Cisplatin_48h |
| SA194193 | healthy_B_EA_B6_4_1_2 | Cisplatin_48h |
| SA194194 | healthy_B_EA_B6_3_1_2 | Cisplatin_48h |
| SA194195 | healthy_B_EA_B6_2_1_2 | Cisplatin_48h |
| SA194196 | healthy_B_EA_A4_4_1_2 | Control_12h |
| SA194197 | healthy_B_EA_A4_3_1_2 | Control_12h |
| SA194198 | healthy_B_EA_A4_5b_1_2 | Control_12h |
| SA194199 | healthy_B_EA_A4_2b_1_2 | Control_12h |
| SA194200 | healthy_B_EA_A4_1b_1_2 | Control_12h |
| SA194201 | healthy_B_EA_A2_5_1_2 | Control_1h |
| SA194202 | healthy_B_EA_A2_2_1_2 | Control_1h |
| SA194203 | healthy_B_EA_A2_3_1_2 | Control_1h |
| SA194204 | healthy_B_EA_A2_4_1_2 | Control_1h |
| SA194205 | healthy_B_EA_A2_1_1_2 | Control_1h |
| SA194206 | healthy_B_EA_A6_3_1_2 | Control_48h |
| SA194207 | healthy_B_EA_A6_4b_1_2 | Control_48h |
| SA194208 | healthy_B_EA_A6_2_1_2 | Control_48h |
| SA194209 | healthy_B_EA_A6_1_1_2 | Control_48h |
| SA194210 | healthy_B_EA_C4_1_1_2 | Pd2Spermine_12h |
| SA194211 | healthy_B_EA_C4_3_1_2 | Pd2Spermine_12h |
| SA194212 | healthy_B_EA_C4_5_1_2 | Pd2Spermine_12h |
| SA194213 | healthy_B_EA_C4_2_1_2 | Pd2Spermine_12h |
| SA194214 | healthy_B_EA_C4_4_1_2 | Pd2Spermine_12h |
| SA194215 | healthy_B_EA_C2_2b_1_2 | Pd2Spermine_1h |
| SA194216 | healthy_B_EA_C2_5_1_2 | Pd2Spermine_1h |
| SA194217 | healthy_B_EA_C2_1b_1_2 | Pd2Spermine_1h |
| SA194218 | healthy_B_EA_C2_3_1_2 | Pd2Spermine_1h |
| SA194219 | healthy_B_EA_C2_4_1_2 | Pd2Spermine_1h |
| SA194220 | healthy_B_EA_C6_5_1_2 | Pd2Spermine_48h |
| SA194221 | healthy_B_EA_C6_4_1_2 | Pd2Spermine_48h |
| SA194222 | healthy_B_EA_C6_2_1_2 | Pd2Spermine_48h |
| SA194223 | healthy_B_EA_C6_1_1_2 | Pd2Spermine_48h |
| SA194224 | healthy_B_EA_C6_3_1_2 | Pd2Spermine_48h |
| Showing results 1 to 44 of 44 |
Collection:
| Collection ID: | CO002139 |
| Collection Summary: | After the respective post-injection time, the mice were sacrificed with pentobarbital injection and the brain was excised, snap-frozen and stored at -80 ºC. |
| Sample Type: | Brain |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR002158 |
| Treatment Summary: | Fifteen animals per group were injected with single doses of cisplatin (3.5 mg/kg b.w.), Pd2Spermine (3.0 mg/kg b.w.) and phosphate-buffered saline solution as controls (200 uL). Five animals of each group were sacrificed at 1, 12 and 48 h post-injection times. |
| Treatment Route: | Intraperitoneal injection |
| Treatment Dosevolume: | 200 uL |
| Treatment Vehicle: | PBS (phosphate-buffered saline solution) |
Sample Preparation:
| Sampleprep ID: | SP002152 |
| Sampleprep Summary: | The frontal cortex of each mice brain was mechanically grounded in liquid nitrogen and samples were extracted using the biphasic methanol/ chloroform/ water (2:2:1) method. Aqueous phase was recovered and dried. Previously to NMR acquisition, aqueous extracts were suspended in 650 µL of 100 mM sodium phosphate buffer (pH 7.4, in D2O containing 0.25% 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid (TSP) for chemical shift referencing). Samples were then homogenized and transferred into 5mm NMR tubes. |
| Processing Storage Conditions: | -80℃ |
| Extraction Method: | Biphasic method (methanol/ chloroform/ water) |
| Extract Storage: | -80℃ |
Analysis:
| Analysis ID: | AN003363 |
| Laboratory Name: | Metabolomics Ana M. Gil |
| Analysis Type: | NMR |
| Acquisition Date: | December 2020 |
| Software Version: | Topspin 3.2 |
| Results File: | matrix_bioimpact_healthy_EA_brain.txt |
| Units: | ppm |
NMR:
| NMR ID: | NM000228 |
| Analysis ID: | AN003363 |
| Instrument Name: | Avance III TM HD 500MHz |
| Instrument Type: | FT-NMR |
| NMR Experiment Type: | 1D-1H |
| Field Frequency Lock: | Deuterium |
| Spectrometer Frequency: | 500MHz |
| NMR Probe: | TXI |
| NMR Solvent: | D2O |
| NMR Tube Size: | 5mm |
| Shimming Method: | Topshim |
| Receiver Gain: | 203 |
| Temperature: | 298K |
| Number Of Scans: | 512 |
| Acquisition Time: | 2.34s |
| Relaxation Delay: | 2s |
| Spectral Width: | 7002.801 |
| Zero Filling: | 64k |
| Baseline Correction Method: | Manual |
| Chemical Shift Ref Std: | TSP (3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid) |
